43 results about "Combination chemotherapy" patented technology

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

The invention discloses a pharmaceutical composition for resisting tumors, and belongs to the field of medical biology. The STING antagonist can be used in combination with chemotherapy drugs to enhance the inhibition effect on tumors, the endoplasmic reticulum stress inducer can also be used in combination with chemotherapy drugs to achieve a better inhibition effect on tumors, and a good tumor inhibition effect is achieved in vivo and in vitro by combining chemotherapy, STING inhibition and endoplasmic reticulum stress treatment schemes. The invention provides a new medication idea for tumor treatment.

The present invention provides the use of plasma small extracellular vesicle miRNA markers in the preparation of a product for predicting the efficacy of combined immunotherapy and chemotherapy for lung cancer. The plasma small extracellular vesicle miRNA markers include: any one of miR-96-5p, miR-99b-3p, miR-100-5p, miR-193a-5p, miR-320d or miR-6815-5p, or a combination of at least two. The present invention models multiple sEVs miRNA combinations and identifies effective models containing two or three sEV miRNAs to determine the true responding population, showing high performance with an AUC greater than 0.9, achieving the potential benefit population for combined immunotherapy and chemotherapy of lung adenocarcinoma screened from the level of peripheral blood small extracellular vesicles.

This invention provides the application of Jiawei Xihuang Pill (MXHP) in the preparation of drugs for the prevention and / or treatment of malignant tumors. This invention also provides the application of Jiawei Xihuang Pill in combination with chemotherapy drugs for the prevention and / or treatment of malignant tumors, particularly glioblastoma multiforme (GBM), wherein the active ingredients of Jiawei Xihuang Pill are prepared from bezoar, musk, vinegar-processed frankincense, vinegar-processed myrrh, and Panax notoginseng root extract in a weight ratio of 14-16:14-16:545-555:545-555:245-255. MXHP can synergistically inhibit the growth of glioblastoma in situ and induce tumor cell apoptosis, indicating that MXHP may be a potential therapeutic drug. Furthermore, compared to XHP, MXHP significantly prolongs the median survival of GBM, exhibiting an enhanced anti-GBM effect.

The present disclosure relates to methods of treating a tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of a T-cell checkpoint inhibitor in combination with chemotherapy and / or radiation therapy, wherein the subject has reduced levels of CD73 protein or CD73 activity compared to a normal subject. In some embodiments, the method further comprises administering a CD73 inhibitor prior to or concurrently with the combined T-cell checkpoint inhibitor and chemotherapy and / or radiation therapy.

The invention discloses a cascade response type drug delivery system targeting matrix-rich solid tumors as well as a construction method and application of the cascade response type drug delivery system, and belongs to the technical field of biological medicines. The cascade response type drug delivery system is composed of a polymer core and a lipid shell layer, the polymer core has the function of responding to high-level glutathione / esterase in tumor cells to release anti-tumor drugs, and the lipid shell layer can target the tumor cells and make FAP-alpha + CAFs static. According to the drug delivery system provided by the invention, the defects of poor responsiveness, insufficient intra-tumor infiltration and relatively low immunogenicity of the existing immunotherapy are overcome, and the combined chemotherapy immunotherapy curative effect of the matrix-rich solid tumor is remarkably improved.

The application discloses a kind of block copolymer and its preparation method and application, the application designs and synthesizes a kind of block copolymer mPEG-PLG-COOH-CD, utilize the host molecule β-CD with guest molecule IDO-1 inhibitor (such as Epa) and Pt class chemotherapy drug (such as cisplatin) with large cavity structure, by hydrophilic and hydrophobic interaction, host-guest recognition, coordination effect common assembly into supramolecular nanomedicine.Supramolecular nanomedicine simultaneously carries Pt class chemotherapy drug and IDO-1 inhibitor.Under the action of weak acid in tumor cell, nanomedicine swells, expose drug, and high concentration of Cl- will destroy the non-covalent bond force inside nanomedicine, quickly release chemotherapy drug and IDO-1 inhibitor, while activating chemotherapy and immunotherapy, realize the efficient combination of two kinds of therapy.In situ activation of chemotherapy not only directly kills cancer cells, but also activates the anti-tumor immunity of body.

The invention provides a pharmaceutical composition and application thereof in preparation of medicines for treating ovarian cancer, and the pharmaceutical composition is prepared from the following components in parts by weight: 5-20 parts of cortex phellodendri, 5-20 parts of rhizoma atractylodis, 5-20 parts of radix achyranthis bidentatae, 5-20 parts of oldenlandia diffusa, 5-20 parts of radix trichosanthis, 5-20 parts of cassia twig, 20-40 parts of radix astragali and 20-40 parts of semen coicis. The pharmaceutical composition provided by the invention is suitable for ovarian cancer postoperative combined chemotherapy, and can significantly reduce the incidence rate of adverse reactions of chemotherapy, improve the chemotherapy effect and compliance, and reduce the toxic and side effects of chemotherapy drugs.

The invention belongs to the technical field of biological medicines, and particularly relates to a group of markers for predicting serious adverse reactions of wide-period small cell lung cancer immune combined chemotherapy and application thereof. The biomarker combination is easy and convenient to sample, and biopsy tissue does not need to be provided. The total T cell percentage is CD3 + / CD45 +, the T cell toxic cell percentage is CD3 + / CD8 + / CD45 +, and the combined combination of the two can predict the occurrence of treatment-related adverse reactions greater than or equal to level 3 of a wide-period small cell lung cancer patient treated by ICI combined chemotherapy, and the combined prediction efficiency is superior to that of a single index. In the training set, the area under the AUC curve of the combined prediction model is 0.852, the optimal Cut-off value is 0.39, the sensitivity is 87.5%, and the specificity is 83.3%. In the constructed prediction model by applying independent external verification, the AUC of the combined prediction model is 0.847, the sensitivity of the model is 85.2%, and the specificity is 73.9%. The method has practicability, and provides precise treatment guidance for clinical medicine.

Provided are pharmaceutical compositions for reducing a tumor burden in a subject having a cancer comprising a combination therapy comprising a therapeutically effective dose of a modified CD2 polypeptide derived from human or rat domain one of CD2 polypeptide and a second therapeutic agent comprising an immune checkpoint inhibitor. Also provided are methods of inhibiting or reducing tumor growth and methods of synergistically increasing the activity of an anti-PD-L1 immunotherapeutic in a subject having a cancer comprising administering the pharmaceutical compositions.

The invention discloses a precise tumor chemoradiotherapy drug delivery device, which relates to the technical field of medical instruments, and comprises an injection host and a high-precision peristaltic pump mounted in the injection host, and further comprises a drug storage mechanism, a movable loosening and clamping assembly and a leakage detection assembly. During use, three independent cabin seats are arranged in the medicine storage mechanism, three medicine storage devices are clamped in the three independent cabin seats respectively, loading of three chemotherapeutic medicines can be completed in advance, frequent replacement of medicine storage cylinders is not needed, ordered infusion of the three medicines is achieved through opening and closing of a controllable communication valve in the gathering pipeline assembly, the treatment time is shortened, infusion continuity is improved, and the treatment efficiency is improved. In addition, in the medicine injection process, all the sensors detect medicine leakage, pipeline blockage, bubbles and medicine stock in real time, and precise medicine conveying is achieved. And a clamping mechanism is arranged in the module cabin body assembly, so that the medicine storage cylinder can be quickly disassembled and assembled, and the operation is simple and convenient.

The invention discloses saRNA for activating AMBRA1 transcription, modified saRNA and application of the saRNA and the modified saRNA. AMBRA1 is used as a target spot, saRNA sequences targeting an AMBRA1 promoter region are designed, 31 saRNA sequences and saRNA modified by the saRNA sequences are obtained through screening, and the saRNA sequences and the saRNA modified by the saRNA sequences can up-regulate the expression level of AMBRA1 in tumor cells so as to regulate the cell cycle and inhibit the proliferation, migration and invasion ability of the tumor cells. The invention further studies the feasibility of the saRNA combined chemotherapeutic drug as a tumor combined treatment scheme, and the combined administration of the saRNA and the chemotherapeutic drug further significantly inhibits the proliferation ability of tumor cells, increases apoptosis, and enhances the sensitivity of the tumor cells to the chemotherapeutic drug, so that the prognosis of tumor patients is expected to be improved; the saRNA or the modified saRNA provided by the invention has an application prospect in the aspects of preparation of anti-tumor drugs and preparation of anti-tumor drug combined therapy.

The invention discloses a biomarker for predicting the curative effect of gastric cancer and application, and belongs to the technical field of diagnosis and treatment of gastric cancer, the biomarker is derived from a composition of programmed cell death-ligand 1 of exosome and lactic acid, and the biomarker can be used for preparing a kit for predicting the curative effect of gastric cancer and a system for predicting the curative effect of gastric cancer. Tests prove that before a gastric cancer patient is treated, the exosome PD-L1 content is lower than 55.24 pg / ml, the exosome lactic acid content is lower than 3.68 ng / mu g, and a good curative effect prediction effect is shown when PD-1 immune blocking combined chemotherapy is accepted. The invention also provides a combined predictive factor which is formed aiming at two detection indexes of exosome PD-L1 and lactic acid and has a better gastric cancer curative effect prediction effect, and the combined predictive factor can be used for accurately predicting the curative effect of a gastric cancer patient after the gastric cancer patient receives first-line treatment. The clinical application value of the exosome PD-L1 and lactic acid as the combined marker in predicting the curative effect of the gastric cancer is further verified.

The present invention discloses a target for tumor treatment and efficacy prediction and its application. The target for tumor treatment and efficacy prediction is MDA5, and also provides the application of MDA5 as a target in treating tumors and as a marker for predicting patient prognosis. The invention proves that MDA5 is an important immunomodulatory factor for colorectal cancer, liver cancer cells, etc. In subcutaneous tumor models of colorectal cancer and liver cancer cell lines in mice, knocking out MDA5 can block and inhibit the occurrence and progression of colorectal cancer and liver cancer, and significantly prolong the survival of tumor-bearing mice. At the same time, targeting MDA5 and combining it with chemotherapy or immune checkpoint inhibitors can more effectively treat and eliminate tumors. MDA5 can be used as a biomarker for poor clinical prognosis of various tumors and can be used to predict patient survival. It provides new ideas for clinical tumor treatment and efficacy prediction, and is expected to provide patients with more acceptable and clinically feasible diagnostic and treatment plans.

The application discloses application of a reagent for detecting HN1L expression in preparation of an esophageal squamous carcinoma diagnosis kit. Through in-vitro and in-vivo function experiments, it is found that knocking down HN1L can inhibit esophageal squamous carcinoma cell metastasis and proliferation, and improve the sensitivity of tumor cells to chemotherapeutic drugs, so that HN1L can be used as a specific marker gene for diagnosing esophageal squamous carcinoma, and the diagnosis of esophageal squamous carcinoma is more accurate and rapid. HN1L can also be used as a drug target for preparing a drug for treating esophageal squamous carcinoma, and a new effective treatment scheme, i.e. a treatment scheme of targeting HN1L combined with a chemotherapeutic drug for treating esophageal squamous carcinoma, is provided, so that a new way for treating esophageal squamous carcinoma is provided.

The application discloses a biomarker combination and application thereof in predicting treatment effect of gastric cancer. The biomarker combination can predict the gastric cancer effect of a gastric cancer patient receiving a Herceptin combined XELOX chemotherapy treatment, has the advantages of high sensitivity and high specificity, and provides favorable technical support for predicting the gastric cancer patient receiving the Herceptin combined XELOX chemotherapy treatment.

This invention discloses an ODC1 gene biomarker for prognostic assessment of lung adenocarcinoma treated with pemetrexed / cisplatin combined chemotherapy and its application. Firstly, it proposes the application of the ODC1 gene in the preparation of reagents for prognostic assessment of lung adenocarcinoma treated with pemetrexed / cisplatin combined chemotherapy. The ENSEMBLE number for the ODC1 gene is ENST00000234111.9. Secondly, it proposes a kit for assessing the sensitivity of lung adenocarcinoma to pemetrexed / cisplatin combined chemotherapy, which includes reagents for detecting ODC1 expression levels. Based on cell experiments and clinical data validation, this invention reveals that the ODC1 gene plays a crucial mediating role in ferroptosis, and its expression level is correlated with the sensitivity of cells to ferroptosis inducers and combined chemotherapy treatment. As a biomarker to help predict the sensitivity or tolerance of lung adenocarcinoma patients to chemotherapy, it has significant clinical application value.

The application name is the application of METTL3 inhibitor combined with chemotherapy drugs to cervical cancer. It belongs to the field of antitumor drugs. Experiments prove that METTL3 inhibitor STM2457 can be used to treat cervical cancer; at the same time, it is proved that STM2457 can increase the sensitivity of the chemotherapeutic drug cisplatin for treating cervical cancer. Through experiments, the effect of using METTL3 inhibitor STM2457 alone on the growth of cervical cancer cells is understood; the effect of METTL3 inhibitor STM2457 combined with the chemotherapeutic drug cisplatin on the survival, proliferation and apoptosis-inducing ability of cervical cancer cells is understood; in vivo experiments on animals verify the effect of METTL3 inhibitor STM2457 alone and combined with the chemotherapeutic drug cisplatin on cervical cancer. Through the above methods, new treatment strategies are used to solve the drug resistance of cervical cancer patients, so as to achieve the best effect of treating cervical cancer.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating lung cancer. The traditional Chinese medicine composition comprises 15-60 parts of radix pseudostellariae, 6-24 parts of radix ophiopogonis, 3-12 parts of schisandra chinensis, 6-24 parts of pulp of dogwood fruit, 7-30 parts of wine-processed rhizoma polygonati, 7-30 parts of dandelion, 15-60 parts of oldenlandia diffusa, 5-20 parts of rhizoma sparganii, 4-18 parts of curcuma zedoary, 1-6 parts of taxus chinensis var mairei, 5-20 parts of pericarpium citri reticulatae, 7-30 parts of selfheal, 5-20 parts of platycodon grandiflorum, 15-60 parts of radix ranunculi ternati and 5-20 parts of liquorice. According to the traditional Chinese medicine composition disclosed by the invention, five medicines such as radix pseudostellariae, radix ophiopogonis, schisandra chinensis, polygonatum kingianum and pulp of dogwood fruit can tonify qi and yin, regulate and tonify lung and kidney and regulate lung and kidney simultaneously, and according to different treatment stages of cough and asthma diseases, the medicines such as dandelion, oldenlandia diffusa, rhizoma sparganii and curcuma zedoary are added or reduced according to syndrome differentiation, so that the effects of promoting blood circulation and removing stasis are achieved; combined chemotherapy / targeted therapy can effectively improve the problems of adverse reaction and drug resistance of lung cancer patients, and the effects of reducing toxicity and improving efficacy are achieved.

The invention provides an application of a Jiawei Huang pill (MXHP) in preparation of a medicine for preventing and / or treating malignant tumors. The invention also provides an application of the Jiawei Huang pill combined with a chemotherapy drug in prevention and / or treatment of malignant tumors, especially glioblastoma multiforme (GBM), and the active ingredients of the Jiawei Huang pill are prepared from bezoar, musk, frankincense processed with vinegar, myrrh processed with vinegar and a pseudo-ginseng root extract according to a weight part ratio of (14-16): (14-16): (545-555): (545-555): (245-255). MXHP can cooperate with TMZ to inhibit growth of in-situ glioblastoma and induce apoptosis of tumor cells, which indicates that MXHP may be a potential therapeutic drug, and compared with XHP, MXHP prolongs the median lifetime of GBM and shows an enhanced anti-GBM effect.

The invention provides application of pentafluridol and a pharmaceutical composition thereof in preparation of antitumor drugs. According to the invention, it is found for the first time that penfluridol induces copper death through a PDPK1-AKT1-CTR1 signal axis, and innovative application of existing drugs in the prior art is realized. The invention discloses a new anti-cancer mechanism, and provides a new target for tumor treatment; through preparation of the novel pharmaceutical composition, combined chemotherapy sensitization is realized. The pentafluridol is used as a traditional antipsychotic drug, the drug safety is comprehensively verified, the transformation potential is high, drug redevelopment can be rapidly promoted, and the pentafluridol has clinical application value.

This invention relates to a combination chemotherapy drug for solid tumors, comprising any clinically used chemotherapy drug combined with a mitochondrial extract to form the active pharmaceutical ingredient, wherein the mitochondrial extract and the clinically used chemotherapy drug are each an independent drug delivery unit. Experiments of this invention have demonstrated that the combined use of the mitochondrial extract and the chemotherapy drug effectively enhances the drug's efficacy compared to using the chemotherapy drug alone, thereby improving the therapeutic effect of chemotherapy for solid tumors.

The invention provides bionic manganese-based drug-loaded nanoparticles as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The bionic manganese-based drug-loaded nano-particle provided by the invention comprises a hollow mesoporous manganese dioxide nano-particle, and bovine serum albumin, a monoclonal antibody with an anti-tumor effect and a PD-1 overexpression tumor cell membrane which sequentially coat the outer surface of the hollow mesoporous manganese dioxide nano-particle from inside to outside, the bovine serum albumin and the monoclonal antibody are connected together through an amide condensation reaction between the bovine serum albumin and the monoclonal antibody and HOOC-TK-COOH; an anti-tumor drug is loaded in the hollow mesoporous manganese dioxide nanoparticles. The bionic manganese-based drug-loaded nanoparticles provided by the invention can realize accurate delivery of tumor sites, have good tumor targeting property, and avoid toxic and side effects caused by whole-body circulation of chemotherapeutic drugs; cooperative tumor treatment of an immune drug combined with a chemotherapy drug is realized, a tumor immunosuppression microenvironment can be reversed, and a remarkable tumor suppression effect is achieved.

The invention relates to the technical field of biology, and particularly discloses application of an SUDS3 gene as a combined chemotherapy anti-tumor target. According to the application, the anti-tumor activity of chemotherapeutic drugs (such as cis-platinum, gemcitabine, hydroxyurea and the like) is remarkably improved by specifically inhibiting the expression or function of SUDS3; the application also overcomes the acquired or inherent drug resistance of tumor cells to conventional chemotherapeutic drugs; the application also reduces the dosage of chemotherapeutic drugs, thereby reducing systemic toxicity.

The invention discloses plasma extracellular vesicles miR-140-5p, miR-597-3p and miR-92a-1-5p which can be used as biomarkers for monitoring or prognosing the curative effect of immune combined chemotherapy of lung cancer, so that the plasma extracellular vesicles miR-140-5p, miR-597-3p and miR-92a-1-5p can be used for preparing a chip, a detection reagent or a detection kit for monitoring or prognosing the curative effect of immune combined chemotherapy of lung cancer. The plasma extracellular vesicle miRNA biomarker disclosed by the invention can be used for accurately screening potential people who benefit from lung cancer immune combined chemotherapy, and particularly accurately subdividing and monitoring the curative effect of the people who benefit from lung cancer immune combined chemotherapy.

The present application belongs to the technical field of intelligent medical treatment, and particularly relates to a RAS, BRAF gene wild type colorectal cancer liver metastasis patient curative effect prediction model based on image group characteristics and application thereof. The present application successfully constructs a model for realizing curative effect prediction of RAS, BRAF gene wild type colorectal cancer liver metastasis patients receiving bevacizumab combined with chemotherapy treatment in the late first line based on CT image group characteristics before treatment: the enhanced CT image group data before initial treatment of patients with advanced colorectal cancer liver metastasis at the time of initial diagnosis is collected, 7 image group characteristics are obtained by using 1000 times Lasso-Logistic analysis, and an image group prediction model is constructed by using a multi-factor logistic regression method. The model constructed by the present application has important clinical application and popularization value from the clinical actual problem.

The invention belongs to the technical field of biological medicine, and particularly relates to a wide-period small cell lung cancer immune combined chemotherapy prognostic marker combination and application thereof. The biomarker combination is easy and convenient to sample, biopsy tissue does not need to be provided, and only peripheral blood needs to be taken for detection. The biomarker combination is high in accuracy, training is concentrated, the area under an AUC curve of a combined prediction model is 0.803, the optimal Cut-off value is 0.51, the sensitivity is 83.7%, and the specificity is 76.5%. The combined index prediction efficiency is good, and a single index cannot be predicted. In a constructed prediction model by applying independent external verification, the joint prediction AUC is 0.789, and when 0.51 is a Cut-off value, the sensitivity of the model is 82.1%, and the specificity is 63.6%. The combined index prediction efficiency is good, and a single index cannot be predicted. The method has practicability, and provides precise treatment guidance for clinical medicine.

The application discloses a combined drug for treating tumors; aims to provide a treatment scheme for targeting transport of a chemotherapeutic drug and a metabolic drug, activating a tumor microenvironment, and treating tumor patients by combining chemotherapy, metabolic therapy and immunotherapy; and the technical key point is that an immune-activated biomimetic nanovesicle is used to load a chemotherapeutic drug, doxorubicin hydrochloride (DOX), and a sugar metabolism inhibitor, 2-deoxy-D-glucose (2-DG); wherein: the activated biomimetic nanovesicle highly expresses PD1 molecules, can competitively interact with PD-L1, and can release the inhibition on immune cells; the DOX is a chemotherapeutic drug; the 2-DG is a glycolysis inhibitor, and can inhibit the glycolysis process in cells; and the application belongs to the field of medical biotechnology.

The invention provides an anti-tumor composition as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The anti-tumor composition disclosed by the invention is prepared from the following raw materials in parts by mass: 18 to 22 parts of ginsenoside Rg3, 3 to 7 parts of ginsenoside CK, 28 to 32 parts of ganoderma lucidum polysaccharide, 23 to 27 parts of astragalus polysaccharide, 8 to 12 parts of lentinan, 16 to 20 parts of panax notoginseng saponins, 9 to 11 parts of resveratrol, 13 to 17 parts of curcumin, 6 to 10 parts of dihydromyricetin and 7 to 9 parts of sophocarpidine. The ratio of the total mass of the ganoderan and the astragalus polysaccharide to the total mass of the ginsenoside Rg3 and the panax notoginseng saponins is (1.3-1.6): 1. Through a multi-target and multi-path synergistic effect mechanism, tumor cell proliferation can be directly inhibited, apoptosis can be induced, the cell cycle can be retarded, tumor angiogenesis can be inhibited, the immune function of the body can be enhanced, the antioxidant effect can be exerted, tumor invasion and metastasis can be inhibited, meanwhile, the obvious synergistic and toxicity reducing effects can be shown in combined chemotherapy application, and the application prospect is wide. And a new technical scheme is provided for comprehensive treatment of tumors.

The invention discloses an application of a CEACAM1 gene or protein as a marker in screening a medicine for preventing or treating small cell lung cancer, and belongs to the technical field of molecular biology. The invention provides application of a CEACAM1 gene or protein as a marker in SCLC chemotherapy curative effect monitoring, chemotherapy drug resistance, disease recurrence, small cell lung cancer treatment and improvement of the sensitivity of small cell lung cancer to chemotherapy drugs. The invention discovers that the molecular marker CEACAM1 participates in SCLC and is resistant to EP combined chemotherapy for the first time, and VP-16, DDP or combination of VP-16 and DDP or two drugs (EP) can increase the molecular expression level of CEACAM1 in SCLC cells. The CEACAM1 can be used as a marker for SCLC chemotherapy curative effect monitoring, chemotherapy drug resistance and disease recurrence. The CEACAM1 is taken as a target spot, and a drug for reversing SCLC EP combined chemotherapy drug resistance can be developed.